DBV Technologies announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately, positioning the clinical-stage biopharmaceutical company for potential commercialization of its Viaskin Peanut patch. The appointment comes as DBV expects to submit a Biologics License Application (BLA) for children 4-7 years old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year.
Strategic Leadership for Critical Phase
"Kevin's appointment as Chief Commercial Officer comes at a decisive time for DBV as we anticipate the Viaskin Peanut patch VITESSE Phase 3 topline results in the fourth quarter of this year and Biologics License Application submission in this age group in the first half of 2026," said Daniel Tasse, Chief Executive Officer of DBV Technologies. Tasse emphasized that Trapp has been instrumental to DBV's commercial strategy since 2017 in either a consulting or executive capacity.
In his new role, Trapp will report directly to CEO Daniel Tasse as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin Peanut patch.
Extensive Industry Experience
Trapp brings more than 30 years of experience in the biopharmaceutical industry to his new position. Before rejoining DBV, he served as Managing Director at Biotech Value Advisors (BVA), where he advised biotechnology boards of directors and executive leadership with product strategy, launch planning, and business evaluation.
His career foundation was built at Bristol-Myers Squibb (BMS), where he held roles of increasing responsibility across finance, sales, marketing, and general management. During his tenure at BMS, Trapp managed a approximately $4 billion U.S. specialty and primary care portfolio and was a key stakeholder in the planning and subsequent launches of more than 10 products and indications, including Abilify, Atripla, Reyataz, Orencia, and Daklinza.
Personal Mission and Confidence in Technology
"The mission of launching of the Viaskin Peanut patch has always represented unfinished work for me — the kind that truly matters in the lives of patients," said Trapp. He expressed confidence in the regulatory progress DBV has made in recent years with both the 1-3 and 4-7 year-old programs, stating that the science behind the Viaskin Peanut patch is compelling and the unmet medical need is urgent.
Innovative Treatment Approach
DBV Technologies is developing the Viaskin Peanut patch using epicutaneous immunotherapy (EPIT), a new class of non-invasive treatment designed to modify an individual's underlying allergy. The VIASKIN patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin, seeking to re-educate the immune system to become desensitized to allergens by leveraging the skin's immune tolerizing properties.
The company's food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). Food allergies are caused by a hypersensitive immune reaction and characterized by symptoms varying in severity from mild to life-threatening anaphylaxis, affecting millions of people, including young children.
Company Profile
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, New Jersey. The clinical-stage biopharmaceutical company focuses on developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. The company's ordinary shares are traded on segment B of Euronext Paris (DBV) and its ADSs are traded on the Nasdaq Capital Market (DBVT).
